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There are a number of general principles in the management
of glomerular injury which apply to most or all of the
histologic variants of GN covered by this guideline. In this
chapter, we discuss these general principles to minimize
repetition in the guideline. Where there are specific
applications or exceptions to these general statements, an
expansion and rationale for these variations and/or recom-
mendations are made in each chapter.
Kidney Biopsy
Kidney biopsy is mandatory for diagnosis. It defines the
morphologic patterns of GN that will be reviewed in this
guideline. The single exception to this rule is SSNS in
children. This entity has an operational clinical definition
that is sufficiently robust to direct initial treatment, with the
kidney biopsy reserved for identifying pathology only when
the clinical response is atypical.
Adequacy of kidney biopsy. There are two components in
terms of assessing adequacy of the tissue sample. The first
relates to the size of biopsy necessary to diagnose or exclude a
specific histopathologic pattern with a reasonable level of
confidence, and the second concerns the amount of tissue
needed for an adequate assessment of the amount of acute or
chronic damage present.
In some cases a diagnosis may be possible from
examination of a single glomerulus (e.g., membranous
nephropathy), but generally a substantially larger specimen
is required to ensure that the material reviewed by the
nephropathologist adequately represents the glomerular,
tubular, interstitial, and vascular compartments of the
kidney. In addition, sufficient tissue is needed to perform
not only an examination by light microscopy, but also
immunohistochemical staining to detect immune reactants
(including immunoglobulins and complement components),
and electron microscopy to define precisely the location,
extent and, potentially, the specific characteristics of the
immune deposits. We recognize that electron microscopy is
not routinely available in many parts of the world, but the
additional information defined by this technique may modify
and even change the histologic diagnosis, and may influence
therapeutic decisions; hence, it is recommended whenever
possible.
In some diseases, for example FSGS and necrotizing
glomerulonephritis associated with antineutrophil cytoplas-
mic antibodies (ANCA), lesions are only seen in some
segments of some glomeruli. In these cases, it is important
that the biopsy is examined by light microscopy at several
levels if lesions are not to be missed. If a lesion that affects
only 5% of glomeruli is to be detected or excluded with
95% confidence, then over 20 glomeruli are needed in the
biopsy.1 Although many biopsies will have fewer glomeruli,
it is important to realize that this limits diagnostic accuracy,
especially when the diagnostic lesions are focal and/or
segmental.
An important component of kidney biopsy examination is
the assessment of ‘‘activity’’, that is lesions which are acute
and potentially responsive to specific therapy, and ‘‘chroni-
city’’, where they are not reversible or treatable. As glomeruli
become scarred there is consequent atrophy of the rest of the
nephron with interstitial fibrosis, and it is usually the case in
GN that the degree of chronic irreversible damage is most
easily assessed from the amount of tubular atrophy. The
accuracy of this assessment is increased with larger biopsies.
The assessment of chronic damage from the biopsy must
always be interpreted together with the clinical data to avoid
misinterpretation if the biopsy is taken from a focal cortical
scar. The amount of information that can be derived from
kidney pathology varies substantially in the different GN
types; when of particular relevance, this is addressed
specifically within the appropriate chapters.
Repeat kidney biopsy. Repeat kidney biopsy during
therapy or following a relapse may be informative. There is
no systematic evidence to support recommendations for
when or how often a repeat biopsy is necessary, but given the
invasive nature of the procedure and the low but unavoidable
risks involved, it should be used sparingly. In general, a
decision about the value of a repeat biopsy should be driven
by whether a change in therapy is being considered. More
specifically, a repeat biopsy should be considered:
K when an unexpected deterioration in kidney function
occurs (not compatible with the natural history) that
suggests there may be a change or addition to the primary
diagnosis (e.g., crescentic GN developing in known
membranous nephropathy or interstitial nephritis second-
ary to the drugs being used in the disease management);
K when changes in clinical or laboratory parameters suggest
a change of injury pattern within the same diagnosis (e.g.,
conversion of membranous to diffuse proliferative LN);
K when the relative contributions to the clinical picture of
disease activity and chronicity are unknown, creating
therapeutic uncertainty in regards to intensifying, main-
taining, or reducing therapy;
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K to assist in defining a ‘‘point of no return’’ and to help
define therapeutic futility (i.e., such extensive and
irreversible kidney scarring that no response to available
therapies can be expected).
Assessment of Kidney Function
Key outcome measures for the management of GN include
assessment of kidney function, particularly measurement of
proteinuria and glomerular filtration rate (GFR).
Proteinuria. Whether urine albumin or urine protein
excretion is the preferred measurement to assess glomerular
injury continues to be debated. However, 24-hour protein
excretion remains the reference (‘‘gold standard’’) method for
quantification of proteinuria in patients with GN. It averages
the variation of proteinuria due to the circadian rhythm,
physical activity, and posture. Almost all of the published
clinical trials used in the development of this guideline
utilized 24-hour measurement of proteinuria to assess
responses. Although this method is subject to error due to
over- or under-collection, the simultaneous measurement of
urine creatinine helps to standardize the collection in terms
of completeness, thereby improving its reliability.
Protein-creatinine ratio (PCR) or albumin-creatinine ratio
on a random (‘‘spot’’) urine sample, or a first morning urine
sample, is a practical alternative to 24-hour urine collection.2
It is increasingly used in clinical practice because the sample
is easy to obtain, is not influenced by variation in water
intake or by urinary flow rate. There may still be gender and
racial variations that are not accounted for, given these
factors may modify creatinine generation. There is a
correlation between the protein-creatinine ratio in a random
urine sample and 24-hour protein excretion. Although the
reliability of PCR for the monitoring of proteinuria during
treatment is still not proven, it has practical clinical utility,
especially in children. In some recent studies, urine samples
have been collected over a longer period (e.g., 4 hours) to
address the limitations of ‘‘spot’’ urine samples that can be
influenced by activity and circadian rhythm, but without the
problems associated with a 24-hour urine collections.3 The
correlation of PCR with proteinuria from a 24-hour urine
collection does improve steadily as the collection period is
lengthened. However, there is currently insufficient evidence
to preferentially recommend 24-hour, shorter-timed, or spot
urine collections for proteinuria in the management of GN.
The conventional definition of nephrotic syndrome in the
published literature is proteinuria 43.5 g per 24 hours (in
children, 440mg/m2/hr or PCR 42000mg/g [4200mg/
mmol] or 4300mg/dl or 3þ on urine dipstick) plus hypo-
albuminemia and edema. Nephrotic-range proteinuria is
nearly always arbitrarily defined as proteinuria 43.5 g per
24 hours [uPCR42000mg/g [4200mg/mmol] in children)
in the absence of clinically overt nephrotic syndrome.
Asymptomatic proteinuria, by definition without clinical
symptoms, has variable levels of proteinuria in the range of
0.3–1.5 g per 24 hours (or equivalent). Treatment trials even
within the same pattern of GN have used a variety of entry
criteria based on severity of proteinuria. This is only one of
the issues that make direct comparison of trial outcomes
difficult. Nevertheless, quantifying proteinuria (and perhaps
even assessing its qualitative nature) is an important measure
in the assessment of the patient with GN. This is relevant in
almost all the primary and secondary glomerular diseases in
this guideline. It is also important and necessary to define,
within each of the specific GN types in the subsequent
chapters, what levels and changes in proteinuria have been
used to categorize both the risk of progression and the
definition of response. These parameters are not uniform and
vary widely across the spectrum of GN. There is insufficient
evidence currently to recommend basing treatment decisions
on more detailed qualitative analysis of proteinuria, such as
measurement of fractional urinary excretion of immuno-
globulin G (IgG), b-2 microglobulin, retinol-binding protein,
or a-1 macroglobulin.
Estimation of GFR. Most of the available evidence for
treatment of GN has been based on estimations of excretory
kidney function using serum creatinine (SCr) or creatinine
clearance (CrCl) requiring a 24-hour urine collection. Very
few studies have reported gold standard measurements of
GFR using inulin or radioisotope clearance techniques. Other
techniques used in past studies include adjustment of SCr for
age, weight, and sex using the Cockcroft-Gault formula and
reciprocal or log transformation of SCr. Serum cystatin C, as
an alternative to SCr has not been validated in subjects with
GN. All these methods have limitations, but are informative
when sequential measurements are made in each subject.
Recently, estimation of GFR using the Modification of
Diet in Renal Disease (MDRD) 4 variable equation has
gained increasing acceptance, although it has not been
validated specifically in those with GN. Another estimating
equation, CKD Epi has recently been proposed, which may
be more accurate than the MDRD equation, especially at
values 460ml/min. Ethnicity may also influence estimated
glomerular filtration rate (eGFR). There is no robust
evidence to recommend the superiority of any of the
available methods for estimating GFR in the management
of GN. One particular limitation is that eGFR using
creatinine-based formulas should be interpreted with caution
in nephrotic syndrome, since tubular creatinine handling is
altered in this condition. As a result, CrCl and eGFR may
overestimate true GFR in nephrotic syndrome by 50% or
more.4 GFR estimations are also unreliable during episodes of
acute kidney injury (AKI).
In children, there are alternative validated formulas for
eGFR, notably the Schwartz formula.
Outcome Measures
Complete remission, ESRD, mortality. A definitive assess-
ment of the efficacy of a treatment for GN requires the
demonstration that end-stage renal disease (ESRD) has been
prevented, and mortality reduced. Very few studies in GN
have been of sufficient duration or have analyzed sufficient
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numbers of patients to accurately assess these outcomes. This
is not surprising, given the slow natural history of many of
the histologic variants of GN in this guideline. The other
accepted outcome measure for many of these disorders is
complete remission, assessed by the complete disappearance
of abnormal proteinuria (o300mg per 24 hours). However,
most studies rely on other surrogates as predictors of clinical
outcomes. These surrogate outcome measures include
changes in proteinuria, e.g., partial remission of proteinuria,
change in kidney function, ‘‘point of no return’’, quality of
life, and quality of health.
Changes in proteinuria. A quantitative change in protei-
nuria is presented in most studies. This is often categorized
as complete remission, usually defined as proteinuria o0.3 g
per 24 hours (uPCRo300mg/g [o30mg/mmol]) or partial
remission defined as proteinuria 40.3 but o3.5 g per
24 hours or a decrease in proteinuria by at least 50% from
the initial value and o3.5 g per 24 hours. However,
definitions vary and are not used consistently even within a
specific GN pattern. The variations in these definitions will
be discussed in each chapter.
Changes in kidney function. Changes in kidney function
are usually measured by changes in SCr or CrCl. These need
to be substantial to indicate true disease progression, e.g.,
doubling of SCr, or halving of CrCl or eGFR. This is because
most patients with GN have gradual changes in function and
there are many factors that may modify the SCr value besides
progression of kidney disease. These factors include changes
in intravascular volume, intercurrent illness, comorbid
conditions, and many drugs. In addition, there are specific
issues related to the SCr value independent of the disease,
such as the method used for its measurement, changes in
muscle mass, and alterations in urine flow and level of kidney
function that both alter the tubular secretion of creatinine.
In more recent studies, changes over time in eGFR have been
reported. In the absence of ESRD as a defined adverse
outcome, slope of CrCl or slope of eGFR may be an adequate
and reliable marker of change in kidney function, provided
that sufficient data at sequential time points are available, and
that the slope is sufficiently linear.5
Changes in GFR are often described qualitatively as
‘‘deteriorating’’ or ‘‘rapidly deteriorating’’ kidney function.
Although these terms have no precise definitions, they are in
common usage especially in certain histologic categories such
as vasculitis and lupus nephritis. These are descriptive terms,
and the value of a particular therapy can be properly
evaluated only when compared to another group with similar
clinical and histologic characterizations and in the setting of
a randomized controlled trial (RCT). Where available, these
will be presented in each chapter.
‘‘Point of no return’’. This concept has no precise defini-
tion, but describes a situation in the natural history of a
chronic glomerular disease where loss of kidney function is
accompanied by such extensive and irreversible kidney injury
that any therapeutic strategy being tested cannot reasonably
be expected to alter the natural history of progressive
deterioration in kidney function (therapeutic futility). The
presumption is that such patients should be excluded from
clinical trials, since they are expected to be ‘‘nonresponders’’
and therefore may dilute any treatment effect, and adversely
affect the power of the study. Furthermore these subjects with
reduced kidney function may be at higher risk of adverse
effects of the therapies being tested. In the absence of precise
definitions of the ‘point of no return’’ it is not possible to
know, in most of the published trials, whether the inclusion
or exclusion of such patients may have masked any
therapeutic benefit.
Quality of life and quality of health. Patients’ own percep-
tions of their quality of life and quality of health, and their
preferences are extremely important elements of the assess-
ment of therapy, but are often an underappreciated and/or
unmeasured parameter in the evaluation of many of the
clinical trials reviewed in this guideline. This is particularly
relevant when considering the risk-benefit analysis of
interventions, which may include the short- and long-term
risks of immunosuppressive treatments but often does not
account for the patient’s perspective in relationship to real or
perceived impact on their quality of life. These unassessed
elements have the potential to significantly obfuscate out-
comes (e.g., concerns about body image in young females
treated with corticosteroids could impact adherence to
therapy). The recent introduction of patient-related out-
comes (PROMS) that allows a more rapid assessment has the
potential to provide a more uniform quality-of-life determi-
nation that is standard across all chronic diseases.
The lack of such data is a substantial evidence gap in the
evaluation of studies relating to the management of GN.
Impact of Age, Sex, Ethnicity, and Genetic Background
Published RCTs of treatment for GN remain few, and many
are small, short in duration of follow-up, and of variable
quality. This has resulted in uncertainty about general-
izability, i.e., whether the demonstrated benefits (or lack of
efficacy) of any treatments will still emerge if patients are
then treated who come from different ethnic groups, and/or
are of different age or sex, compared to those included in the
published studies. The specific limitations of studies in this
regard are discussed in later chapters but the following are
examples of this issue: whether it is reasonable to extrapolate
treatment recommendations from children to adults with
MCD, and vice versa; whether the effectiveness of regimens
for LN proven in Caucasians can be extended to those of
other ethnicities; and whether the safety observed with a
course of immunosuppression in the young applies equally to
the elderly.
Furthermore few available RCTs are statistically powered
to examine less-common adverse effects of therapy. It is not
yet clear if new insights into these and other issues will
emerge from a better understanding of the pharmacogenetic
variations that can substantially alter the pharmacokinetics
and/or pharmacodynamics of immunosuppressive and other
agents. Although early evidence is suggestive that such
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genetic traits may alter clinical outcome,6 the cost of such
pharmacogenetic testing also needs consideration and, as yet,
there is little robust evidence that these factors should modify
the treatment of GN.
Management of Complications of Glomerular Disease
A number of complications of glomerular disease are a
consequence of the clinical presentation rather than the
specific histolopathologic pattern. Active management of
such complications—although not subject to evidence review
in this guideline—should always be considered and may have
a significant positive impact on the natural history of the
disease. These include measures to treat blood pressure,
reduce proteinuria, control edema, and address other
metabolic and thrombophilic consequences of nephrotic
syndrome, which can result in significant morbidity and even
mortality. If successful, these relatively nontoxic therapies
may prevent—or at least modulate—the need for immuno-
suppressive drugs with their potential adverse effects. Such
supportive therapy is usually not necessary in steroid-
sensitive MCD with rapid remission, or in patients with
GN and only microscopic hematuria, preserved GFR, and
neither proteinuria nor hypertension. The latter is a common
scenario, for instance, in IgA nephropathy.
Hypertension. As in all chronic kidney disease (CKD), the
aim of blood pressure control is both to protect against the
cardiovascular risks of hypertension and to delay progressive
loss of GFR. Lifestyle modification (salt restriction, weight
normalization, regular exercise, and smoking cessation)
should be an integral part of the therapy for blood pressure
control.
The ideal goal for blood pressure is not firmly established
but current recommendations suggest that 130/80mmHg
should be the treatment goal. There are limited data to
support a lower target of 125/75mmHg if there is protein-
uria 41 g/d.7 This issue will be covered in a forthcoming
KDIGO Guideline for the Management of Blood Pressure in
Chronic Kidney Disease. There is no specific evidence in GN
on which to base a recommendation about the preferential
importance of systolic or diastolic blood pressure, or about
timing of blood pressure measurements. There are strong
theoretical and experimental reasons for angiotensin-
converting enzyme inhibitors (ACE-I) and angiotensin-
receptor blockers (ARB) to be first-choice therapy; this is
now well-documented in clinical studies.8 Children with GN
should have blood pressure controlled to below the 50th
percentile for systolic and diastolic pressure for age and sex
using published9,10 or locally available standards.
The evidence for blood pressure goals and choice of
antihypertensive therapy in GN and other CKD has not been
systematically evaluated for this guideline; it will be the
subject of a forthcoming KDIGO Clinical Practice Guideline.
Proteinuria. Reduction in proteinuria is important, as
it reflects control of the primary disease, reduction of
glomerular hypertension, and also reduction of podocyte
damage (a likely major factor in glomerular scarring).
Most studies suggest that the loss of kidney function in the
progressive histologic patterns discussed in this guideline can
largely be prevented if proteinuria can be reduced to levels
below 0.5 g/d. The exceptions are MCD and SSNS where
complete remission defines the disease. Proteinuria or factors
present in proteinuric urine may also be toxic to the
tubulointerstitium. In nephrotic syndrome, a reduction of
proteinuria to a non-nephrotic range often results in an
elevation to normal of serum proteins (particularly albumin).
This elevation, in turn, alleviates many of the patient’s
symptoms as well as the metabolic complications of the
nephrotic syndrome, thus improving quality of life.
The antiproteinuric agents of choice are ACE-I or ARB,
which may reduce proteinuria by up to 40–50% in a dose-
dependent manner, particularly if the patient complies with
dietary salt restriction. There is little evidence to suggest that
ACE-I differ from ARBs in this respect. However, the
combination of the two may result in additive antiproteinuric
activity, although there is conflicting evidence as to the risk-
benefit ratio of this strategy, especially if GFR is significantly
reduced. Since ACE-I and ARBs lower GFR, a 10–20%
increase in SCr is often observed. Unless SCr continues to
rise, this moderate increase reflects their effect on kidney
hemodynamics and not worsening disease, and should not
prompt withdrawal of the medication.
Recommendations on the dosing of these agents and the
target levels of proteinuria are outside the scope of this
introduction, but are addressed when there is available
evidence for specific forms of GN in subsequent chapters.
Adequate dietary protein should be ensured in the
proteinuric patient (0.8–1.0 g/kg daily) with a high carbohy-
drate intake to maximize utilization of that protein.
The evidence for the benefit of reducing proteinuria in
CKD in general, and the choice of specific agents, has not
been systematically evaluated for this guideline with the
exception of the value of partial remission discussed in the
relevant chapters. The evidence for renal protective therapy
will be the subject of a forthcoming KDIGO Clinical Practice
Guideline on Evaluation and Management of Chronic Kidney
Disease.
Hyperlipidemia. Treatment of hyperlipidemia in patients
with glomerular disease should usually follow the guidelines
that apply to those at high risk for the development of
cardiovascular disease. This is most relevant in the patients
where the manifestations of the disease cannot be completely
ameliorated, and when other risk factors for cardiovascular
disease coexist, most commonly hypertension and protein-
uria. Dietary restriction of fats and cholesterol alone has only
modest effects on hyperlipidemia in glomerular disease, in
particular in nephrotic syndrome. Statins (HMG CoA
reductase inhibitors) are well tolerated and effective in
correcting the lipid profile, although not proven to reduce
cardiovascular events in nephrotic syndrome. It may also
be that statin therapy protects from a decline in GFR,
although this is not established. Care is needed when statins
are used in combinations with other drugs, notably an
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increased risk of myalgia/myositis when combined with
calcineurin inhibitors.
Nephrotic edema. The mainstay of treatment is diuretics
accompanied by moderate dietary sodium restriction (1.5–2 g
[60–80mmol] sodium per 24 hours). Nephrotic patients are
often diuretic-resistant even if GFR is normal: oral loop
diuretics with once- or twice-daily administration are usually
preferred, given the ease of administration and longer
therapeutic effect compared to i.v. therapy. However, in
severe nephrotic syndrome, gastrointestinal absorption of the
diuretic may be uncertain because of intestinal-wall edema,
and i.v. diuretic, by bolus injection or infusion, may be
necessary to provoke an effective diuresis. Alternatively,
combining a loop diuretic with a thiazide diuretic or with
metolazone is often an effective oral regimen that may
overcome ‘‘diuretic resistance’’. i.v. albumin infusions may be
combined with diuretics to treat diuretic resistance, but are of
unproven benefit. Occasionally, mechanical ultrafiltration is
required for resistant edema.
Significant hypovolemia is not often a clinical problem,
provided that fluid removal is controlled and gradual, but the
pediatric and the elderly populations are at more risk of this
complication. In the elderly, associated conditions such as
diabetes mellitus and hypertension may increase the like-
lihood of hypovolemic shock and acute ischemic kidney
injury.
Hypercoagulability. The risk of thrombotic events be-
comes progressively more likely as serum albumin values fall
below 2.5 g/dl (25 g/l). Immobility as a consequence of
edema, obesity, malignancy, intercurrent illness, or admission
to hospital for surgery can further aggravate the risk.
Prophylactic low-dose anticoagulation (e.g., heparin 5000
units subcutaneously twice daily) is common practice at
times of high risk. Full-dose anticoagulation with low-
molecular-weight heparin or warfarin is mandatory if an
arterial or venous thrombosis, or pulmonary embolism, is
documented. It should also be considered if serum albumin
drops below 2.0–2.5 g/dl (20–25 g/l) with one or more of the
following: proteinuria 410 g/d; body mass index (BMI)
435 kg/m2; family history of thromboembolism with
documented genetic predisposition; New York Heart Asso-
ciation class III or IV congestive heart failure; recent
abdominal or orthopedic surgery; or prolonged immobiliza-
tion. Contraindications to prophylactic anticoagulation are:
an uncooperative patient; a bleeding disorder; prior gastro-
intestinal bleeding; a central nervous lesion prone to
hemorrhage (brain tumor, aneurysms); or a genetic abnorm-
ality influencing warfarin metabolism or efficacy.
During treatment with heparin, a significantly higher than
average dose may be required because part of the action of
heparin depends on antithrombin III, which may be lost in
the urine in the nephrotic patient. Warfarin is the long-term
treatment of choice but should be monitored with special
care because of potential alterations in the protein binding of
the drug with fluctuations in serum albumin in the nephrotic
patient. A target international normalized ratio (INR) of 2–3
is usually recommended, although not supported by specific
evidence.
Risk of infection. A high order of clinical vigilance for
bacterial infection is vital in nephrotic patients. This is
particularly important in nephrotic children with ascites, in
whom the fluid should be examined microscopically and
cultured for spontaneous bacterial peritonitis. Bacteremia
can occur even if clinical signs are localized to the abdomen.
Erythrocyte sedimentation rate is unhelpful, but an elevated
C-reactive protein may be informative. Parenteral antibiotics
should be started once cultures are taken and the regimen
should include benzylpenicillin (to treat pneumococcal
infection). If repeated infections occur, serum immuno-
globulins should be measured. If serum IgG is less than
600mg/dl (6 g/l), there is limited evidence that infection risk
is reduced by monthly administration of i.v. immunoglobulin
10–15 g to keep serum IgG 4600mg/dl (46 g/l).11
Those with GN and nephrotic syndrome are at increased
risk of invasive pneumococcal infection and should receive
pneumococcal vaccination with the heptavalent conjugate
vaccine (7vPCV) and the 23-valent polysaccharide vaccine
(23vPPV) as well as the annual influenza vaccination. The
response does not seem to be impaired by concurrent
corticosteroid therapy. Vaccination with live vaccines
(measles, mumps, rubella, varicella, rotavirus, yellow fever)
is contraindicated while on immunosuppressive or cytotoxic
agents, and should be deferred until prednisone dose is
o20mg/d and/or immunosuppressive agents have been
stopped for at least 1–3 months. Exposure to varicella can
be life-threatening, especially in children. Treatment should
be given with zoster immune globulin if exposure does occur
and antiviral therapy with acyclovir or valaciclovir begun at
the first sign of chicken pox lesions12 (See Chapter 3, SSNS,
for additional details on management in children).
Use of Corticosteroids and Immunosuppressive Therapy
The chapters that follow will focus on the effectiveness of
therapy based on current evidence in the most common
histologic variants of GN.
The therapeutic decisions of the physician are predicated
on the continuing need to balance the risks and benefits of
treatment. Nothing stated in this guideline replaces the
physician’s assessment in this regard. The physician ideally
seeks a treatment regimen that reduces immunosuppressive
therapy exposure to the minimum, minimizes immediate
morbidity (e.g., achieving remission of nephrotic syndrome),
and prevents disease progression. However, physicians must
also recognize that more prolonged treatment may be
required, given the long-term threat that failure to prevent
ESRD will shorten life expectancy and may only delay
prolonged immunosuppressive drug exposure that would be
required after kidney transplantation.
The focus in the management of chronic patterns of GN
has shifted from cure to control, exemplified by recognition
of the short- and long-term benefits of a reduction in
proteinuria (in addition to the benefits known to accrue with
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complete remission). This paradigm has translated into use
of more extended (or repeated) treatment regimens with the
corollary of more toxic drug exposure.
The specific adverse effects of the recommended immu-
nosuppressive agents and the need for routine prophylactic
measures are beyond the scope of this guideline, but are
familiar in clinical practice, and have been reviewed.13
Specific regimens that potentially require prolonged exposure
to these immunosuppressive agents are identified in the
chapters to follow.
Adverse effects. The potential adverse effects of immu-
nosuppressive therapy must always be discussed with the
patient and family before treatment is initiated. This part of
the management cannot be overemphasized. The risks of
treatment with many of the agents are significant and may
have a substantial latent period (e.g., cyclophosphamide).
A balance must be struck between the potential risks of
immunosuppressive treatment for GN, and the seriousness of
the patient’s condition. It is sometimes difficult to reconcile
the immediate risks of immunosuppression, in the otherwise
clinically well patient, vs. the potential for progression to
ESRD. However, given that advanced CKD—and, particu-
larly, ESRD—is associated with a significant shortening of life
expectancy even with dialysis or transplantation, the
balancing of risks and benefits over time must be considered.
The physician must be aware of this conundrum and where
the evidence for treatment is weak (but potentially life-
altering) and the risk for harm strong, a full disclosure
is mandatory. Individual patient perceptions of the accept-
ability of any adverse effect may strongly influence the
decision (e.g., the possibility of hirsutism with cyclosporin
therapy may be perceived as less tolerable in a young female
than in an older male). What might be seen as an accept-
able trade-off by the physician may not be viewed similarly
by the patient, leading to an issue over compliance with
therapy.
With more intensive immunosuppressive regimens, pro-
phylaxis may be required to minimize possible adverse
effects. Specific recommendations are beyond the scope of
this guideline, and are without an evidence base specific to
treatment of GN, but better evidenced when immuno-
suppression is used in kidney transplantation. Common
examples are the use of prophylactic antimicrobials to
minimize opportunistic infection, and H2-receptor antago-
nists or proton pump inhibitors to prevent peptic ulceration.
Two other important and more drug-specific examples are
the use of bisphosphonates (except in the presence of kidney
failure) to minimize loss of bone density during prolonged
treatment with corticosteroids, and the need to offer the
opportunity for sperm or ovum storage/preservation—where
available—before treatment with the gonadotoxic agents,
cyclophosphamide and chlorambucil.
Drug monitoring. Immunosuppressive agents with a
narrow therapeutic index include the calcineurin inhibitors,
cyclosporin and tacrolimus. There are no RCTs that compare
response to treatment in GN and different achieved blood
levels of these agents. Dosing and target blood levels are based
on established practice in kidney transplantation. The main
goal of blood level monitoring is to avoid toxicity due to high
drug levels, while still maintaining efficacy. The latter can
often be assessed by proteinuria reduction, which can
sometimes be achieved with trough blood levels of calcineur-
in inhibitors that would be considered subtherapeutic for
solid-organ transplantation. The value of monitoring myco-
phenolic acid levels to guide dosing of mycophenolate has
not been studied in GN.
Pregnancy in Women with GN
In women of child-bearing potential, the risks of pregnancy
must be considered. A major predictor of pregnancy outcome
is the GFR at time of conception. Other issues include the
toxicity, especially in the first trimester, of immunosuppres-
sive agents, ACE-I, and ARBs, and also the hazards to fetal
and maternal outcome of pregnancy with uncontrolled
proteinuric conditions. There is also a risk of relapse of LN
both during and after pregnancy.
Treatment Costs and Related Issues
These guidelines have been developed with the goal of
providing evidence-based treatment recommendations for
GN that can be used by physicians in all parts of the world.
Most of the medications recommended are available at low
cost in many parts of the world. These include prednisone,
azathioprine, and cyclophosphamide tablets. Monitoring
(e.g., by regular checks of blood count) is also cheap and
widely available.
The cost of some agents (e.g., calcineurin inhibitors and
mycophenolate) remains high, but the development and
marketing of generic agents and biosimilars is now rapidly
reducing costs. However, care must be taken to ensure that
variations in bioavailablity with these less expensive generic
agents do not compromise effectiveness or safety.
Plasmapheresis remains unavailable in some parts of
the world, related not only to the high cost and limited
availability of replacement fluids (including human albumin
and fresh frozen plasma) but also to the equipment and
staffing costs.
Some treatments suggested as potential ‘‘rescue’’ therapies
in this guideline (e.g., rituximab) remain prohibitively
expensive in most parts of the world. This is another
indication of the urgent need for developing trials that will
provide robust evidence of their efficacy. Uncertainty about
the value of such high-cost agents would also be mitigated if
there were comprehensive national or international registries
collecting comprehensive observational data on their use, but
unfortunately none exist.
Post-transplantation GN
Virtually all of the histologic variants discussed in this
guideline (with the exception of MCD) may recur after
transplantation. Recurrent disease is recognized as the third
most common cause of kidney transplant failure. Currently
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there are no proven strategies to prevent recurrent GN in
kidney transplant recipients. Despite the high rate of
recurrent disease, long-term graft survival is still very good
and transplantation remains the best treatment option for
patients with ESRD secondary to GN. Where there are
specific recommendations in particular variants of GN that
relate to management before transplantation, they will be
discussed in each relevant chapter.
RESEARCH RECOMMENDATIONS
The evidence review underpinning this clinical practice
guideline has confirmed the paucity of robust data from
RCTs to support the treatment recommendations and
suggestions that have been made. This raises the question
of why there are so few RCTs of good design and sufficient
power in GN, compared to many other areas of nephrology
and internal medicine. The slowly progressive natural history
of many patterns of GN means that trials designed to provide
definitive outcome data (using ESRD or mortality) require
long follow-up, significantly increasing their cost as well as
effort for both the physician and the patient. Studies often
employ ‘‘composite end-points’’ in order to enhance event
rates. Furthermore, there are two competing elements in GN
trial design. On the one hand, there is the recognition that
most GN variants are uncommon; on the other hand, there is
a need to acquire an adequate sample size within a reasonable
time frame, an essential element for any successful study.
This virtually mandates multicenter and multinational trial
organization which, in turn, is challenging from both
organizational and cost perspectives. These factors have
made trials in GN less attractive both to funding agencies and
pharmaceutical companies, compared to more common and
higher-profile clinical domains such as cardiovascular disease
and cancer.
However there is an urgent need for such studies to be
carried out. The costs—both to society, and to patients with
GN and their families, if disease progression is not
prevented—are often grossly underestimated. As an integral
part of this guideline, we make recommendations in each
chapter about the most pressing areas of uncertainty where
RCTs and other areas of research would significantly inform
clinical practice.
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